Structure–activity relationships of urotensin II and URP

Archive ouverte

Leprince, Jérôme | Chatenet, David | Dubessy, Christophe | Fournier, Alain | Pfeiffer, Bruno | Scalbert, Elizabeth | Renard, Pierre | Pacaud, Pierre | Oulyadi, Hassan | Ségalas-Milazzo, Isabelle | Guilhaudis, Laure | Davoust, Daniel | Tonon, Marie-Christine | Vaudry, Hubert

Edité par CCSD ; Elsevier -

International audience. Urotensin II (U-II) and urotensin II-related peptide (URP) are the endogenous ligands for the orphan G-protein-coupled receptor GPR14 now renamed UT. At the periphery, U-II and/or URP exert a wide range of biological effects on cardiovascular tissues, airway smooth muscles, kidney and endocrine glands, while central administration of U-II elicits various behavioral and cardiovascular responses. There is also evidence that U-II and/or URP may be involved in a number of pathological conditions including heart failure, atherosclerosis, renal dysfunction and diabetes. Because of the potential involvement of the urotensinergic system in various physiopathological processes, there is need for the rational design of potent and selective ligands for the UT receptor. Structure-activity relationship studies have shown that the minimal sequence required to retain full biological activity is the conserved U-II(4-11) domain, in particular the Cys5 and Cys10 residues involved in the disulfide bridge, and the Phe6, Lys8 and Tyr9 residues. Free alpha-amino group and C-terminal COOH group are not necessary for the biological activity, and modifications of these radicals may even increase the stability of the analogs. Punctual substitution of native amino acids, notably Phe6 and Trp7, by particular residues generates analogs with antagonistic properties. These studies, which provide crucial information regarding the structural and conformational requirements for ligand-receptor interactions, will be of considerable importance for the design of novel UT ligands with increased selectivity, potency and stability, that may eventually lead to the development of innovative drugs.

Consulter en ligne

Suggestions

Du même auteur

Structure–activity relationships and structural conformation of a novel urotensin II-related peptide

Archive ouverte | Chatenet, David | CCSD

International audience. Urotensin II (UII) has been described as the most potent vasoconstrictor peptide and recognized as the endogenous ligand of the orphan G protein-coupled receptor GPR14. Recently, a UII-relate...

Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 2004. Proceedings of the 3rd International and 28th European Symposium, pp 804-805

Archive ouverte | Chatenet, David | CCSD

International audience

Structure−Activity Relationships of a Novel Series of Urotensin II Analogues: Identification of a Urotensin II Antagonist

Archive ouverte | Chatenet, David | CCSD

International audience. Urotensin II (U-II) is a potent vasoconstrictor peptide which has been identified as the endogenous ligand for the orphan G protein-coupled receptor GPR14 now renamed UT receptor. As the C-te...

Chargement des enrichissements...